BioCryst

$5.14
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.37 (+7.77%) Today

+$0.01 (+0.19%) As of 7:18 AM EST after-hours

Why Robinhood?

You can buy or sell BioCryst and other stocks, options, and ETFs commission-free!

About BCRX

BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC. The listed name for BCRX is BioCryst Pharmaceuticals, Inc. Common Stock.

CEO

Jon P. Stonehouse

Employees

140

Headquarters

Durham, North Carolina

Founded

1986

Market Cap

905.78M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

4.89M

High Today

$5.12

Low Today

$4.80

Open Price

$4.81

Volume

3.80M

52 Week High

$6.29

52 Week Low

$1.58

Collections

Research And Development

Analyst Ratings

70%

of 10 ratings

Buy

70%

Hold

30%

Sell

BCRX Earnings

-$0.34

-$0.23

-$0.11

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 4, Pre-Market